Ignite Creation Date:
2025-12-24 @ 1:02 PM
Ignite Modification Date:
2026-02-11 @ 6:12 AM
Study NCT ID:
NCT03099161
Status:
TERMINATED
Last Update Posted:
2019-06-05
First Post:
2017-03-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-06-27
Start Date Type:
ACTUAL
Primary Completion Date:
2017-11-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-02-21
Completion Date Type:
ACTUAL
First Submit Date:
2017-03-30
First Submit QC Date:
None
Study First Post Date:
2017-04-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2018-09-07
Results First Submit QC Date:
None
Results First Post Date:
2019-06-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-02-25
Last Update Post Date:
2019-06-05
Last Update Post Date Type:
ACTUAL